Anti-carcinogenic Effect of Cathepsin K Inhibitor, Odanacatib with a Low Dose of Cisplatin Against Human Breast Carcinoma MCF-7 and MDA-MB231 Cells

Author(s): Yaongamphi Vashum, Amuthavalli Kottaiswamy, Tholcopiyan Loganathan, Fathima B. Sheriff, Shila Samuel*

Journal Name: Current Cancer Therapy Reviews

Volume 17 , Issue 2 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: A cross-linking agent commonly used for cancer chemotherapy is a platinum compound such as cisplatin. However, with the acquisition of cellular drug resistance and adverse side effects, the potency of cisplatin is, therefore, often tempered. To overcome these issues, the present study has established the use of cathepsin k (CTSK) inhibitor as a potent chemosensitizer.

Methods: The cytotoxic effect of cisplatin and odanacatib (ODN) on two different breast cancer patient- derived cell lines, MDA-MB-231 and MCF-7, was assessed by MTT-based colorimetric assay. The drug interaction coefficient CDI was used to evaluate the synergistically inhibitory impact of the drug combination and immunoblot was used to examine the expression of certain proteins responsible for cell survival and the mechanism of apoptosis.

Results: In this study, we found that IC50 of ODN in combination with cisplatin (half of IC25) induced a synergistic cytotoxic effect in different breast cancer cells. Diminished expression of Bcl-2 and increased expression of Bax aroused the cytochrome release, that triggered caspase-9 and -3 activation in the combinatorial group. ODN with a lower dose of cisplatin significantly inhibited the protein expression of novel chemoresistant factors such as STAT3, NFκB and IL-6.

Conclusion: This study highlights the potential effects of the combination of ODN with a reduced dose of cisplatin on improving the growth inhibition and apoptosis-inducing effect on breast cancer cells via combined inhibition of NF-κB-induced IL-6 and STAT3 activation. The study result suggests that the further development of this novel inhibitor in combination with a low dose of standard cisplatin-based chemotherapy may contribute to an alternative treatment option for certain cancers.

Keywords: Breast cancer, chemoresistance, cathepsin K, odanacatib, cisplatin, synergism, apoptosis.

[1]
Redig AJ, McAllister SS. Breast cancer as a systemic disease: A view of metastasis. J Intern Med 2013; 274(2): 113-26.
[http://dx.doi.org/10.1111/joim.12084] [PMID: 23844915]
[2]
Yardley DA. Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer 2013; 2013: 137414.
[http://dx.doi.org/10.1155/2013/137414] [PMID: 23864953]
[3]
Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12(4): 237-51.
[http://dx.doi.org/10.1038/nrc3237] [PMID: 22437869]
[4]
Brömme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs 2009; 18(5): 585-600.
[http://dx.doi.org/10.1517/13543780902832661] [PMID: 19388876]
[5]
Drake MT, Clarke BL, Oursler MJ, Khosla S, Cathepsin K. Cathepsin K inhibitors for osteoporosis: Biology, potential clinical utility, and lessons learned. Endocr Rev 2017; 38(4): 325-50.
[http://dx.doi.org/10.1210/er.2015-1114] [PMID: 28651365]
[6]
Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007; 6(1): 60-4.
[http://dx.doi.org/10.4161/cc.6.1.3669] [PMID: 17245112]
[7]
Mason SD, Joyce JA. Proteolytic networks in cancer. Trends Cell Biol 2011; 21(4): 228-37.
[http://dx.doi.org/10.1016/j.tcb.2010.12.002] [PMID: 21232958]
[8]
Reinheckel T, Peters C, Krüger A, Turk B, Vasiljeva O. Differential impact of cysteine cathepsins on genetic mouse models of de novo carcinogenesis: Cathepsin B as emerging therapeutic target. Front Pharmacol 2012; 3: 133.
[http://dx.doi.org/10.3389/fphar.2012.00133] [PMID: 22798952]
[9]
Goel S, Wang Q, Watt AC, et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell 2016; 14;29(3): 255-69.
[10]
Rapa I, Volante M, Cappia S, Rosas R, Scagliotti GV, Papotti M. Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth. Am J Clin Pathol 2006; 125(6): 847-54.
[http://dx.doi.org/10.1309/Q96AYDAAJ3E1TNWT] [PMID: 16690483]
[11]
Littlewood-Evans AJ, Bilbe G, Bowler WB, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 1997; 1;57(23): 5386-90.
[12]
Brubaker KD, Vessella RL, True LD, Thomas R, Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 2003; 18(2): 222-30.
[http://dx.doi.org/10.1359/jbmr.2003.18.2.222] [PMID: 12568399]
[13]
Česen MH, Pegan K, Spes A, Turk B. Lysosomal pathways to cell death and their therapeutic applications. Exp Cell Res 2012; 318(11): 1245-51.
[http://dx.doi.org/10.1016/j.yexcr.2012.03.005] [PMID: 22465226]
[14]
Aits S, Jäättelä M. Lysosomal cell death at a glance. J Cell Sci 2013; 126(Pt 9): 1905-12.
[http://dx.doi.org/10.1242/jcs.091181] [PMID: 23720375]
[15]
Turk V, Stoka V, Vasiljeva O, et al. Cysteine cathepsins: From structure, function and regulation to new frontiers. Biochim Biophys Acta 2012; 1824(1): 68-88.
[http://dx.doi.org/10.1016/j.bbapap.2011.10.002] [PMID: 22024571]
[16]
Seo HR, Bae S, Lee YS. Radiation-induced cathepsin S is involved in radioresistance. Int J Cancer 2009; 124(8): 1794-801.
[http://dx.doi.org/10.1002/ijc.24095] [PMID: 19101991]
[17]
Zheng G, Martignoni G, Antonescu C, et al. A broad survey of cathepsin K immunoreactivity in human neoplasms. Am J Clin Pathol 2013; 139(2): 151-9.
[http://dx.doi.org/10.1309/AJCPDTRTO2Z4UEXD] [PMID: 23355199]
[18]
Zheng X, Chu F, Chou PM, et al. Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: A putative mechanism. Am J Physiol Cell Physiol 2009; 296(1): C65-74.
[http://dx.doi.org/10.1152/ajpcell.00082.2008] [PMID: 18971393]
[19]
Jacquemont C, Simon JA, D’Andrea AD, Taniguchi T. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Mol Cancer 2012; 11: 26.
[http://dx.doi.org/10.1186/1476-4598-11-26] [PMID: 22537224]
[20]
Shree T, Olson OC, Elie BT, et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 2011; 25(23): 2465-79.
[http://dx.doi.org/10.1101/gad.180331.111] [PMID: 22156207]
[21]
Lee TK, Cheung VC, Lu P, et al. Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 2014; 60(1): 179-91.
[http://dx.doi.org/10.1002/hep.27070] [PMID: 24523067]
[22]
Dickson MA, Carvajal RD, Merrill AH Jr, Gonen M, Cane LM, Schwartz GK. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res 2011; 17(8): 2484-92.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-2323] [PMID: 21257722]
[23]
Nishiyama N, Okazaki S, Cabral H, et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 2003; 63(24): 8977-83.
[PMID: 14695216]
[24]
Lekakis L, Tryfonopoulos D, Pistamatzian N, et al. Salvage chemotherapy with cisplatin and 5-fluorouracil in metastatic breast cancer. Particular activity against liver metastases. Anticancer Res 2012; 32(5): 1833-7.
[PMID: 22593470]
[25]
Sun S, Tang L, Zhang J, et al. Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. Int J Nanomedicine 2014; 9: 1443-52.
[PMID: 24672237]
[26]
Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs 2003; 63(15): 1549-63.
[http://dx.doi.org/10.2165/00003495-200363150-00003] [PMID: 12887262]
[27]
Sims JT, Ganguly SS, Bennett H, Friend JW, Tepe J, Plattner R. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PLoS One 2013; 8(1): e55509.
[http://dx.doi.org/10.1371/journal.pone.0055509] [PMID: 23383209]
[28]
Keitel U, Scheel A, Thomale J, et al. Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation. Oncotarget 2014; 5(23): 11778-91.
[http://dx.doi.org/10.18632/oncotarget.2634] [PMID: 25473892]
[29]
O’Reilly S, Ciechomska M, Cant R, van Laar JM. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J Biol Chem 2014; 289(14): 9952-60.
[http://dx.doi.org/10.1074/jbc.M113.545822] [PMID: 24550394]
[30]
Tu Y, Renner S, Xu F, et al. BCL-X expression in multiple myeloma: Possible indicator of chemoresistance. Cancer Res 1998; 58(2): 256-62.
[PMID: 9443402]
[31]
Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10(1): 105-15.
[http://dx.doi.org/10.1016/S1074-7613(00)80011-4] [PMID: 10023775]
[32]
Horie N, Hirabayashi N, Takahashi Y, Miyauchi Y, Taguchi H, Takeishi K. Synergistic effect of green tea catechins on cell growth and apoptosis induction in gastric carcinoma cells. Biol Pharm Bull 2005; 28(4): 574-9.
[http://dx.doi.org/10.1248/bpb.28.574] [PMID: 15802789]
[33]
Weldon CB, Burow ME, Rolfe KW, Clayton JL, Jaffe BM, Beckman BS. NF-kappa B-mediated chemoresistance in breast cancer cells. Surgery 2001; 130(2): 143-50.
[http://dx.doi.org/10.1067/msy.2001.115512] [PMID: 11490342]
[34]
Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 2010; 376(9737): 235-44.
[http://dx.doi.org/10.1016/S0140-6736(10)60892-6] [PMID: 20609467]
[35]
Shevtsov M, Multhoff G, Mikhaylova E, Shibata A, Guzhova I, Margulis B. Combination of anti-cancer drugs with molecular chaperone inhibitors. Int J Mol Sci 2019; 20(21): 5284.
[http://dx.doi.org/10.3390/ijms20215284] [PMID: 31652993]
[36]
Hao L, Chen W, McConnell M, et al. A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease. Infect Immun 2015; 83(4): 1235-45.
[http://dx.doi.org/10.1128/IAI.01713-14] [PMID: 25583522]
[37]
Yang SX, Polley E, Lipkowitz S. New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev 2016; 45: 87-96.
[http://dx.doi.org/10.1016/j.ctrv.2016.03.004] [PMID: 26995633]
[38]
Spitzner M, Roesler B, Bielfeld C, et al. STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo. Int J Cancer 2014; 134(4): 997-1007.
[http://dx.doi.org/10.1002/ijc.28429] [PMID: 23934972]
[39]
Nessa MU, Beale P, Chan C, Yu JQ, Huq F. Studies on combination of platinum drugs cisplatin and oxaliplatin with phytochemicals anethole and curcumin in ovarian tumour models. Anticancer Res 2012; 32(11): 4843-50.
[PMID: 23155250]
[40]
Bharti AC, Aggarwal BB. Chemopreventive agents induce suppression of nuclear factor-kappaB leading to chemosensitization. Ann N Y Acad Sci 2002; 973: 392-5.
[http://dx.doi.org/10.1111/j.1749-6632.2002.tb04671.x] [PMID: 12485899]
[41]
Godwin P, Baird AM, Heavey S, Barr MP, O’Byrne KJ, Gately K. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol 2013; 3: 120.
[http://dx.doi.org/10.3389/fonc.2013.00120] [PMID: 23720710]
[42]
Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011; 19(2): 192-205.
[http://dx.doi.org/10.1016/j.ccr.2010.12.022] [PMID: 21295524]
[43]
Hussain AR, Ahmed SO, Ahmed M, et al. Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS One 2012; 7(6): e39945.
[http://dx.doi.org/10.1371/journal.pone.0039945] [PMID: 22768179]
[44]
Kwon O, Kim KA, Kim SO, et al. NF-kappaB inhibition increases chemosensitivity to trichostatin A-induced cell death of Ki-Ras- transformed human prostate epithelial cells. Carcinogenesis 2006; 27(11): 2258-68.
[http://dx.doi.org/10.1093/carcin/bgl097] [PMID: 16774937]
[45]
Hua Y, Xu X, Shi GP, Chicco AJ, Ren J, Nair S. Cathepsin K knockout alleviates pressure overload-induced cardiac hypertrophy. Hypertension 2013; 61(6): 1184-92.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.00947] [PMID: 23529168]
[46]
Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615-27.
[http://dx.doi.org/10.1146/annurev.med.53.082901.103929] [PMID: 11818492]
[47]
Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 Study. J Clin Oncol 2007; 25(19): 2664-70.
[http://dx.doi.org/10.1200/JCO.2006.08.8054] [PMID: 17563395]
[48]
Chawla-Sarkar M, Lindner DJ, Liu Y-F, et al. Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8(3): 237-49.
[http://dx.doi.org/10.1023/A:1023668705040] [PMID: 12766484]
[49]
Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87(1): 99-163.
[http://dx.doi.org/10.1152/physrev.00013.2006] [PMID: 17237344]
[50]
Qin JJ, Yan L, Zhang J, Zhang WD. STAT3 as a potential therapeutic target in triple negative breast cancer: A systematic review. J Exp Clin Cancer Res 2019; 38(1): 195.
[http://dx.doi.org/10.1186/s13046-019-1206-z] [PMID: 31088482]
[51]
Yang W, Ko H, Kim H, Kim M. The effect of cathepsin K inhibitor on osteoclastic activity compared to alendronate and enamel matrix protein. Dent Traumatol 2015; 31(3): 202-8.
[http://dx.doi.org/10.1111/edt.12152] [PMID: 25394885]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 2
Year: 2021
Published on: 21 December, 2020
Page: [159 - 169]
Pages: 11
DOI: 10.2174/1573394716666201222101925
Price: $65

Article Metrics

PDF: 130
HTML: 2